I think that liquid biopsy, that is, using urine or peripheral blood samples will revolutionize cancer care and pathology over time.  Right now testing may be more limited with limited clinical trials but over time I think liquid biopsy will...

Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, recently announced the availability of the ConcordiaT cell-free DNA (cfDNA) purification sample...

Interesting article by Kathy Liszewski over at Genetic Engineering and Biotechnology News looking at circulating tumor cells (CTCs) incorporated with digital pathology. There is little doubt in my mind that technologies involving CTCs,...

New trial is open to patients who have completed standard treatments; Goal is to determine if cancer recurrences can be detected earlier and lead to improved targeted outcomes. Cynvenio Biosystems, Inc., a diagnostics company dedicated to...

Irvine, CA (September 10, 2015) – WaveSense has named two veteran health care executives to top leadership positions and received a multi-million dollar capital investment to drive the company’s growth. WaveSense is the developer of the...

Had the opportunity to attend ASCO last week with a few goals in mind: Get updates on current trends in oncology management as oncologists are common clients of pathologists and laboratories. Spend some time in the exhibit area to see how...